Adaptive clinical trial designs for phase I cancer studies (Q2452091)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: Adaptive clinical trial designs for phase I cancer studies |
scientific article; zbMATH DE number 6299051
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | No label defined |
||
| English | Adaptive clinical trial designs for phase I cancer studies |
scientific article; zbMATH DE number 6299051 |
Statements
Adaptive clinical trial designs for phase I cancer studies (English)
0 references
30 May 2014
0 references
Bayesian designs
0 references
``best intention'' designs
0 references
continual reassessment method
0 references
dose finding studies
0 references
estimation efficiency
0 references
ethics
0 references
maximum tolerated dose
0 references
oncology trial designs
0 references
optimal designs
0 references
phase I
0 references
stochastic approximation
0 references
toxicity
0 references
up-and-down designs
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0.8111053705215454
0 references
0.8051793575286865
0 references
0.8016278147697449
0 references
0.7911123037338257
0 references
